Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct:Chapter 10:Unit10.1.
doi: 10.1002/0471142301.ns1001s49.

Assessment of Parkinson disease manifestations

Affiliations

Assessment of Parkinson disease manifestations

Joel S Perlmutter. Curr Protoc Neurosci. 2009 Oct.

Abstract

Parkinson disease (PD) is a progressive neurologic condition that causes motor and nonmotor manifestations. Treatment provides symptomatic benefit but no current treatment has been proven to slow disease progression. Research studies of PD require a means of rating the severity of disease by measurement of motor manifestations, assessment of ability to perform daily functional activities, and symptomatic response to medication. The most common rating scales are the Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr staging, and the Schwab and England rating of activities of daily living. Each of these rating scales are described, including detailed instructions on how to implement these ratings. Although these are the most widely applied rating scales of PD, there are still substantial limitations to these scales that must be considered when using them for research. Finally, some common applications of these scales are described.

PubMed Disclaimer

References

    1. Chan PL, Nutt JG, Holford NH. Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson’s disease. J. Pharmacokinet. Pharmacodyn. 2004;31:243–268. - PubMed
    1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006;5:235–245. - PubMed
    1. Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 2003;991:1–14. - PubMed
    1. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. 2004;351:2498–2508. - PubMed
    1. Goetz C. Re: UPDRS: Status and recommendations. Mov. Disord. 2004;19:605. - PubMed

Publication types

MeSH terms

Substances